149 related articles for article (PubMed ID: 9316818)
21. Melphalan monitoring during hyperthermic perfusion of isolated limb for melanoma: pharmacokinetic study and 99mTc-albumin microcolloid technique.
Cattel L; Buffa E; De Simone M; Cesana P; Novello S; Dosio F; Ceruti M
Anticancer Res; 2001; 21(3C):2243-8. PubMed ID: 11501854
[TBL] [Abstract][Full Text] [Related]
22. Reversal of stereoselectivity in the hepatic availability of verapamil in isolated perfused rat livers. Role of protein binding.
Mehvar R; Reynolds J
Drug Metab Dispos; 1996 Oct; 24(10):1088-94. PubMed ID: 8894509
[TBL] [Abstract][Full Text] [Related]
23. Uptake of lipophilic model compounds into the isolated perfused rat epididymal adipose tissue.
Gubser R; Di Francesco C; Bickel MH
J Pharmacol Exp Ther; 1986 Jun; 237(3):967-71. PubMed ID: 3086542
[TBL] [Abstract][Full Text] [Related]
24. Isolated rat kidney perfused with dextran and bovine serum albumin: a stable model for investigating renal drug handling.
Wang J; Nation RL; Evans AM; Cox S
J Pharmacol Toxicol Methods; 2004; 49(2):105-13. PubMed ID: 14990335
[TBL] [Abstract][Full Text] [Related]
25. Reduction of dimesna to mesna by the isolated perfused rat liver.
Goren MP; Hsu LC; Li JT
Cancer Res; 1998 Oct; 58(19):4358-62. PubMed ID: 9766664
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities.
Briele HA; Djuric M; Jung DT; Mortell T; Patel MK; Das Gupta TK
Cancer Res; 1985 Apr; 45(4):1885-9. PubMed ID: 3978649
[TBL] [Abstract][Full Text] [Related]
27. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
[TBL] [Abstract][Full Text] [Related]
28. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver.
Vahrmeijer AL; van Dierendonck JH; Keizer HJ; Beijnen JH; Tollenaar RA; Pijl ME; Marinelli A; Kuppen PJ; van Bockel JH; Mulder GJ; van de Velde CJ
Br J Cancer; 2000 May; 82(9):1539-46. PubMed ID: 10789721
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic and phase II study of heated intraoperative intraperitoneal melphalan.
Sugarbaker PH; Stuart OA
Cancer Chemother Pharmacol; 2007 Feb; 59(2):151-5. PubMed ID: 17091250
[TBL] [Abstract][Full Text] [Related]
30. High-performance liquid chromatographic assay for the measurement of melphalan and its hydrolysis products in perfusate and plasma and melphalan in tissues from human and rat isolated limb perfusions.
Wu ZY; Thompson MJ; Roberts MS; Addison RS; Cannell GR; Grabs AJ; Smithers BM
J Chromatogr B Biomed Appl; 1995 Nov; 673(2):267-79. PubMed ID: 8611961
[TBL] [Abstract][Full Text] [Related]
31. Renal transport kinetics of chlorothiazide in the isolated perfused rat kidney.
Lee LJ; Cook JA; Smith DE
J Pharmacol Exp Ther; 1988 Oct; 247(1):203-8. PubMed ID: 3171972
[TBL] [Abstract][Full Text] [Related]
32. Albumin decreases myocardial permeability of unbound quinidine in perfused rat heart.
Morgan DJ; Huang JL
J Pharmacol Exp Ther; 1994 Jan; 268(1):283-90. PubMed ID: 8301569
[TBL] [Abstract][Full Text] [Related]
33. Melphalan concentration and distribution in the tissues of tumour-bearing limbs treated by isolated limb perfusion.
Scott RN; Blackie R; Kerr DJ; Hughes J; Burnside G; MacKie RM; Byrne DS; McKay AJ
Eur J Cancer; 1992; 28A(11):1811-3. PubMed ID: 1389515
[TBL] [Abstract][Full Text] [Related]
34. In-transit melanoma: the role of alkylating-agent resistance in regional therapy.
Grubbs EG; Abdel-Wahab O; Cheng TY; Abdel-Wahab Z; Peterson B; Pruitt SK; Colvin OM; Friedman HS; Tyler DS
J Am Coll Surg; 2004 Sep; 199(3):419-27. PubMed ID: 15325612
[TBL] [Abstract][Full Text] [Related]
35. Improved performance of the isolated rat liver when perfused with purified bovine serum albumin.
Lee D; Holland RK
Transplantation; 1979 Jun; 27(6):384-8. PubMed ID: 462529
[TBL] [Abstract][Full Text] [Related]
36. Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats.
Hoving S; Brunstein F; aan de Wiel-Ambagtsheer G; van Tiel ST; de Boeck G; de Bruijn EA; Eggermont AM; ten Hagen TL
Cancer Res; 2005 May; 65(10):4300-8. PubMed ID: 15899822
[TBL] [Abstract][Full Text] [Related]
37. Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: a clinical and pharmacologic evaluation.
van Iersel LB; Verlaan MR; Vahrmeijer AL; van Persijn van Meerten EL; Tijl FG; Sparidans RW; Gelderblom H; Kuppen PJ; Tollenaar RA; van de Velde CJ
Eur J Surg Oncol; 2007 Sep; 33(7):874-81. PubMed ID: 17400422
[TBL] [Abstract][Full Text] [Related]
38. Isolated lung perfusion with melphalan: pharmacokinetics and toxicity in a pig model.
van der Elst A; Oosterling SJ; Paul MA; Vonk AM; Sparidans RW; van der Sijp JR
J Surg Oncol; 2006 Apr; 93(5):410-6. PubMed ID: 16550578
[TBL] [Abstract][Full Text] [Related]
39. Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response.
Hoving S; Seynhaeve AL; van Tiel ST; aan de Wiel-Ambagtsheer G; de Bruijn EA; Eggermont AM; ten Hagen TL
Anticancer Drugs; 2006 Sep; 17(8):949-59. PubMed ID: 16940805
[TBL] [Abstract][Full Text] [Related]
40. An optimized model for rat liver perfusion studies.
Cheung K; Hickman PE; Potter JM; Walker NI; Jericho M; Haslam R; Roberts MS
J Surg Res; 1996 Nov; 66(1):81-9. PubMed ID: 8954836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
